--Presentations Elucidating Imeglimin’s Unique Mechanism of Action Targeting Mitochondrial Bioenergetics and Confirming Clinical Benefits of this Novel Mechanistic Approach--
LYON, France--(BUSINESS WIRE)-- POXEL (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, announced today that the Company will present new data for its lead program, Imeglimin, at two respected scientific forums in Europe and the US. Specifically, the Company will present at the 6th World Congress on Targeting Mitochondria in Berlin, Germany, October 28-30, 2015. In addition, the Company has had an abstract accepted for poster presentation at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease Congress (WCIR) in Los Angeles, California, November 19-21, 2015.
Targeting Mitochondria Congress
"Imeglimin, a New Mitochondria Targeted Agent for Type 2 Diabetes Treatment" will be presented Friday, October 30th, 9:20 – 10:05 CET. This presentation will provide insights into the unique mitochondrial mechanism of action for Imeglimin leading to its ability to increase both glucose-dependent insulin secretion and sensitivity, the two key defects of Type 2 diabetes.
World Congress on Insulin Resistance and Cardiovascular Diseases
An abstract entitled, "Imeglimin, a New Oral Anti-Hyperglycemic Agent Controls Both Fasting and Post-Prandial Glucose Through an Improvement in Both Insulin Secretion and Insulin Sensitivity," was accepted for poster presentation at the WCIR in November. The data will provide additional detail on Imeglimin’s unique mechanism of action and its clinical benefits for Type 2 diabetes patients in context of the results of an 18-week phase 2 trial, for which the topline results were publicized in June 2015.
Poxel will announce the results through a press release at the time of the data presentations.
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Anca Alexandru, + 49 89 2424 3494
Investor relations / Media - France
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
Released October 7, 2015